Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia

Clinical trial NCT04250051 · TERMINATED

Trial details

NCT number: NCT04250051
Sponsor: Northwestern University
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Recurrent Acute Myeloid Leukemia Recurrent Myelodysplastic Syndrome Recurrent Myeloproliferative Neoplasm Refractory Acute Myeloid Leukemia Refractory Myelodysplastic Syndrome Newly Diagnosed Acute Myeloid Leukemia (AML)IDH1 Mutation Myeloid Neoplasms Acute Myeloid Leukemia (AML)

Start date: 2020-12-21
Primary completion: 2022-01-16
Enrollment: 2

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.